L. Guilloton

Le neurologue et le plongeur : aptitude à la pratique de la plongée de loisir en présence d’une atteinte neurologique

Jean-Éric Blatteau, L. Guilloton, Fabien Zagnoli

fr (code pays fourni par la source)

COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022

Lina Jeantin, Édouard Januel, Pierre Labauge, Élisabeth Maillart et autres

BACKGROUND: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. OBJECTIVES: We aimed to extend these data from the onset of the pandemic to the global …

fr, lu, ch (code pays fourni par la source)

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis

Édouard Januel, David Hajage, Pierre Labauge, Élisabeth Maillart et autres

Importance: In patients with multiple sclerosis (MS), factors associated with severe COVID-19 include anti-CD20 therapies and neurologic disability, but it is still unclear whether these 2 variables are independently associated with severe COVID-19 or whether the association depends on MS clinical course. …

fr (code pays fourni par la source)

Lésions osseuses d’un syndrome POEMS

Cyrielle Genicon, L. Guilloton, Michel Pavic, François Le Moigne

fr, ca (code pays fourni par la source)

Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

Caroline Papeix, Giovanni Castelnovo, Emmanuelle Leray, Marc Coustans et autres

INTRODUCTION: It is important to confirm the effectiveness and tolerability of disease-modifying treatments for relapsing-remitting multiple sclerosis (RRMS) in real-world treatment settings. This prospective observational cohort study (VIRGILE) was performed at the request of the French health authorities. The primary objective was …

fr, se (code pays fourni par la source)

Skeletal lesions in POEMS syndrome

Cyrielle Genicon, L. Guilloton, Michel Pavic, François Le Moigne

us, fr, ca (code pays fourni par la source)

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

Céline Louapre, Nicolas Collongues, Bruno Stankoff, C. Giannesini et autres

Importance: Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. …

fr (code pays fourni par la source)

Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis

Céline Louapre, Nicolas Collongues, Bruno Stankoff, C. Giannesini et autres

Background: Risk factors associated with the severity of COVID- 19 in patients with multiple sclerosis (MS) begin to be identified from several cohort studies Disease modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors …

État de stress post-traumatique et douleurs psychogènes

Julie Defrance, Stéphane Foucher, Eric Ramdani, L. Guilloton et autres

ch, fr (code pays fourni par la source)

A clinical screening tool for objective and subjective cognitive disorders in multiple sclerosis

L. Guilloton, Jean‐Philippe Camdessanché, D. Latombe, Philippe Neuschwander et autres

fr (code pays fourni par la source)

Cognitive disorders in multiple sclerosis: a screening tool proposed in current practice. The experience of the Rhône-Alpes SEP Network

L. Guilloton

Incidence and impact of headaches in the post-traumatic stress disorder (P1.188)

L. Guilloton, Julie Defrance, Pierre Blanc, Marion Trousselard et autres

describe the incidence and the impact of headaches in patients suffering from Post-traumatic disorder.

fr (code pays fourni par la source)